COVID-19 and cardiovascular disease: What we know, what we think we know, and what we need to know

Rahul Dhawan; Rebekah L Gundry; David M Brett-Major; Claudius Mahr; Geoffrey M Thiele; Merry L Lindsey; Daniel R Anderson

doi:10.1016/j.yjmcc.2020.04.026

COVID-19 and cardiovascular disease: What we know, what we think we know, and what we need to know

J Mol Cell Cardiol. 2020 Jul:144:12-14. doi: 10.1016/j.yjmcc.2020.04.026. Epub 2020 Apr 24.

Authors

Rahul Dhawan¹, Rebekah L Gundry², David M Brett-Major³, Claudius Mahr⁴, Geoffrey M Thiele⁵, Merry L Lindsey⁶, Daniel R Anderson⁷

Affiliations

¹ Department of Internal Medicine, Division of Cardiovascular Medicine, University of Nebraska Medical Center, Omaha, NE, United States of America.
² Department of Internal Medicine, Division of Cardiovascular Medicine, University of Nebraska Medical Center, Omaha, NE, United States of America; Department of Cellular and Integrative Physiology, University of Nebraska Medical Center, Omaha, NE, United States of America.
³ Department of Epidemiology, College of Public Health, University of Nebraska Medical Center, Omaha, NE, United States of America.
⁴ Division of Cardiology, University of Washington, Seattle, WA, United States of America.
⁵ Department of Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, United States of America; Research Service, Nebraska-Western Iowa Health Care System, Omaha, NE, United States of America.
⁶ Department of Cellular and Integrative Physiology, University of Nebraska Medical Center, Omaha, NE, United States of America; Research Service, Nebraska-Western Iowa Health Care System, Omaha, NE, United States of America.
⁷ Department of Internal Medicine, Division of Cardiovascular Medicine, University of Nebraska Medical Center, Omaha, NE, United States of America. Electronic address: danderso@unmc.edu.

No abstract available

Keywords: ACE; Angiotensin converting enzyme inhibitors; Angiotensin converting enzyme receptor 2; COVID-19; Cardiovascular disease; Coronavirus; Renin angiotensin system.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Angiotensin Receptor Antagonists / adverse effects
Angiotensin Receptor Antagonists / pharmacology*
Angiotensin-Converting Enzyme 2
Angiotensin-Converting Enzyme Inhibitors / adverse effects
Angiotensin-Converting Enzyme Inhibitors / pharmacology*
Animals
Betacoronavirus / pathogenicity
COVID-19
Cardiovascular Diseases / complications*
Cardiovascular Diseases / drug therapy
Cardiovascular Diseases / physiopathology
Coronavirus Infections / drug therapy
Coronavirus Infections / etiology*
Host-Pathogen Interactions / physiology
Humans
Pandemics
Peptidyl-Dipeptidase A / metabolism*
Pneumonia, Viral / drug therapy
Pneumonia, Viral / etiology*
SARS-CoV-2
Serine Endopeptidases / metabolism
Serine Proteinase Inhibitors / pharmacology

Substances

Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors
Serine Proteinase Inhibitors
Peptidyl-Dipeptidase A
ACE2 protein, human
Angiotensin-Converting Enzyme 2
Serine Endopeptidases
TMPRSS2 protein, human

Publication types

MeSH terms

Substances

Grants and funding